Skip to content

Study · Animal study (in vivo) · mouse and rat · 2009

4 results

Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats.

Barrera JG, D'Alessio DA, Drucker DJ, Woods SC, Seeley RJ

Diabetes9 Sept 2009Cited by 57 (Europe PMC)

PMID19741167 (opens in a new tab)PMCIDPMC2780868 (opens in a new tab)DOI10.2337/db09-0281 (opens in a new tab)PepBankPUB-19741167
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, intracerebroventricular exendin‑4 was 100-fold more potent than GLP-1 at reducing food intake.

    In plain wordsIn rats, brain-administered exendin‑4 reduced food intake more potently than GLP-1.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseFood intake potency
    Study

    ratn: not reported in source

    Intracerebroventricular feeding study
    Comparator
    GLP-1
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (rat).

    Source sentences

    Summary
    Intracerebroventricular Ex4 was 100-fold more potent than GLP-1 at reducing food intake, and this effect was insensitive to GLP-1r antagonism.
    1 context sentence
    Summary · context
    In this study, the anorectic effects of intracerebroventricular GLP-1 and Ex4, and the sensitivity of these effects to GLP-1r antagonism, were compared in rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In GLP-1 receptor knockout mice, intracerebroventricular exendin‑4 failed to reduce food intake.

    In plain wordsIn mice without GLP-1 receptors, brain-administered exendin‑4 did not reduce food intake.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeFood intake in receptor knockout mice
    Study

    mousen: not reported in source

    GLP-1 receptor knockout mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Despite the insensitivity of intracerebroventricular Ex4 to GLP-1r antagonism, intracerebroventricular Ex4 failed to reduce food intake in GLP-1r(-/-) mice.

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 03AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Mechanism

    In rats, GLP-1 receptor antagonism did not block the anorectic effect of intracerebroventricular exendin‑4.

    In plain wordsIn rats, receptor blockers did not block food intake suppression from brain-administered exendin‑4.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeCentral anorectic response under antagonism
    Study

    ratn: not reported in source

    Intracerebroventricular feeding study
    Comparator
    GLP-1 receptor antagonism
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    Intracerebroventricular Ex4 was 100-fold more potent than GLP-1 at reducing food intake, and this effect was insensitive to GLP-1r antagonism.
    1 context sentence
    Summary · context
    In this study, the anorectic effects of intracerebroventricular GLP-1 and Ex4, and the sensitivity of these effects to GLP-1r antagonism, were compared in rats.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 04AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Mechanism

    In rats, GLP-1 receptor antagonists completely blocked the anorectic effect of intraperitoneal exendin‑4.

    In plain wordsIn rats, receptor blockers completely blocked food intake suppression from abdominal exendin‑4 injections.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePeripheral anorectic response under antagonism
    Study

    ratn: not reported in source

    Intracerebroventricular feeding study
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    However, GLP-1r antagonists completely blocked the anorectic effect of intraperitoneal Ex4.
    1 context sentence
    Summary · context
    In this study, the anorectic effects of intracerebroventricular GLP-1 and Ex4, and the sensitivity of these effects to GLP-1r antagonism, were compared in rats.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.